author-photo

Gail Lynn Shaw Wright

Sarah Cannon Research Institute

2

Papers

2

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)